Nab-Paclitaxel as Neoadjuvant Therapy for Breast Cancer

Yu (Amy) Zong
Published: Monday, Jan 09, 2017



Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy of breast cancer.

In a comparison to the commonly used paclitaxel, nab-paclitaxel was used in adjuvant chemotherapy for patients with breast cancer. Developed to avoid solvent-related toxicities, nab-paclitaxel has a higher rate of solubility within the body, which does not put a limit the dosage of the drug, says Zong.

Twenty-one studies with 2357 patients were looked at, with only 3 of them being randomized. The aggregate rate was 32%, but varied in different subgroups.

Although patients experienced peripheral sensory neuropsy events, nab-paclitaxel, and paclitaxel resulted in the same level of toxicities. Hypersensitivity was lower with nab-paclitaxel, reports Zong, leading to the conclusion that nab-paclitaxel is an effective cytotoxic drug in the neoadjuvant setting.

The findings are still early, according to Zong. As for the future, more randomized trials should be conducted to decide whether nab-paclitaxel demonstrates higher efficacy than the other taxane treatments being used currently.
 


Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy of breast cancer.

In a comparison to the commonly used paclitaxel, nab-paclitaxel was used in adjuvant chemotherapy for patients with breast cancer. Developed to avoid solvent-related toxicities, nab-paclitaxel has a higher rate of solubility within the body, which does not put a limit the dosage of the drug, says Zong.

Twenty-one studies with 2357 patients were looked at, with only 3 of them being randomized. The aggregate rate was 32%, but varied in different subgroups.

Although patients experienced peripheral sensory neuropsy events, nab-paclitaxel, and paclitaxel resulted in the same level of toxicities. Hypersensitivity was lower with nab-paclitaxel, reports Zong, leading to the conclusion that nab-paclitaxel is an effective cytotoxic drug in the neoadjuvant setting.

The findings are still early, according to Zong. As for the future, more randomized trials should be conducted to decide whether nab-paclitaxel demonstrates higher efficacy than the other taxane treatments being used currently.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x